Get the Stockscreener App
20.37
4.25%
0.83
After Hours:
20.37
Arcus Biosciences Inc stock is traded at $20.37, with a volume of 1.91M.
It is up +4.25% in the last 24 hours and down -11.40% over the past month.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
See More
Previous Close:
$19.54
Open:
$19.5
24h Volume:
1.91M
Relative Volume:
1.21
Market Cap:
$2.52B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-6.5922
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+7.27%
1M Performance:
-11.40%
6M Performance:
+92.90%
1Y Performance:
+106.17%
1-Day Range:
$19.50
$20.44
1-Week Range:
$18.52
$21.20
52-Week Range:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
20.37 | 2.42B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Call Highlights: S - GuruFocus
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: Arcus Biosciences beats EPS expectations in Q4 2025 - Investing.com Nigeria
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
RCUS: Casdatifan delivers superior efficacy in RCC, driving strong financials and market potential - TradingView
Arcus Biosciences Files For Mixed Shelf - TradingView
RCUS: 2025 net loss widened to $353M on $247M revenue; $1.0B cash supports late-stage pipeline - TradingView
Arcus Biosciences, Inc. SEC 10-K Report - TradingView
Arcus Biosciences Earnings Review: Q4 Summary - Benzinga
Arcus Biosciences Provides Pipeline Update on Its Clinical-Stage Investigational Molecules and Discovery Programs - marketscreener.com
Arcus Biosciences in spotlight: Kidney drug trial results at stake - Investing.com India
Can Arcus Biosciences Inc stock double in the next yearJuly 2025 Decliners & Real-Time Buy Zone Alerts - baoquankhu1.vn
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Report Preview: Wh - GuruFocus
Arcus Biosciences (NYSE:RCUS) Shares Up 10.1%Here's Why - MarketBeat
Market Catalysts: Is Arcus Biosciences Inc in a long term uptrendJuly 2025 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn
Arcus Biosciences (RCUS) Showcases Promising Data for Casdatifan in Cancer Study - GuruFocus
Late-line kidney cancer patients top a year without progression on Arcus drug - Stock Titan
Arcus Biosciences’ cancer drug gets orphan drug status - MSN
Investment Report: Can Arcus Biosciences Inc disrupt its industryTreasury Yields & Consistent Growth Stock Picks - baoquankhu1.vn
Is Arcus Biosciences Inc. stock worth buying before Fed actionWeekly Trade Recap & High Conviction Buy Zone Picks - mfd.ru
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
Aberdeen Group plc Makes New $4.42 Million Investment in Arcus Biosciences, Inc. $RCUS - MarketBeat
Earnings Beat: What’s Arcus Biosciences Inc.’s historical returnTrade Entry Report & Community Supported Trade Ideas - mfd.ru
Arcus Biosciences (RCUS) Stock Analysis: Exploring a 65% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Here's What Analysts Think About Arcus Biosciences (RCUS) - Finviz
Here’s What Analysts Think About Arcus Biosciences (RCUS) - Insider Monkey
A Look At Arcus Biosciences (RCUS) Valuation After Wells Fargo Downgrade And Shifting Analyst Sentiment - Yahoo Finance
How Arcus Biosciences Inc. (RCUS) Affects Rotational Strategy Timing - Stock Traders Daily
What’s Arcus Biosciences Inc.’s historical returnQuarterly Growth Report & Step-by-Step Trade Execution Guides - mfd.ru
Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment - MSN
Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
How cyclical is Arcus Biosciences Inc.’s revenue streamWeekly Trade Report & High Return Trade Opportunity Guides - mfd.ru
RCUS: Wells Fargo Downgrades Arcus Biosciences, Lowers Price Tar - GuruFocus
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
What Analysts Are Saying About Arcus Biosciences Stock - Benzinga
Candriam S.C.A. Takes $5.15 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
Cancer drug developer Arcus sets Feb. 25 call on 2025 results - Stock Titan
Is Arcus Biosciences Inc. stock a smart retirement pickQuarterly Investment Review & Safe Capital Investment Plans - mfd.ru
Arcus Advances Quemliclustat With New Phase 1 Study: What Investors Should Know - TipRanks
Arcus Biosciences stock hits 52-week high at $21.03 By Investing.com - Investing.com South Africa
Arcus Biosciences stock hits 52-week high at $21.03 - Investing.com
Arcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street Zen - MarketBeat
(RCUS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High? - sharewise.com
Aug Decliners: How correlated is Arcus Biosciences Inc to the S P500Portfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Arcus Biosciences, Inc. (RCUS): Analyst Consensus Signals 51% Upside Potential Amid Robust Clinical Pipeline - DirectorsTalk Interviews
What is Arcus Biosciences Inc.’s valuation compared to sectorTrend Reversal & Capital Efficient Trade Techniques - mfd.ru
Arcus Biosciences Grants Stock Options to Employees - intellectia.ai
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):